Amarin tumbles on FDA snub of ANCHOR SPA appeal
This article was originally published in Scrip
Executive Summary
Shares of Amarin fell 13.5% on 22 November after the FDA refused to accept the company's appeal of the agency's rescission of the special protocol assessment (SPA) agreement for the firm's placebo-controlled Phase III ANCHOR study of Vascepa.